TrialInternational journal of hematology2016

Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy.

Yoshitaka Miyakawa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.